Gross Profit Analysis: Comparing Dr. Reddy's Laboratories Limited and Lantheus Holdings, Inc.

Comparative Gross Profit Growth: Dr. Reddy's vs. Lantheus

__timestampDr. Reddy's Laboratories LimitedLantheus Holdings, Inc.
Wednesday, January 1, 201475801000000125519000
Thursday, January 1, 201585403000000135522000
Friday, January 1, 201692281000000137780000
Sunday, January 1, 201778356000000162135000
Monday, January 1, 201876304000000174885000
Tuesday, January 1, 201983430000000174811000
Wednesday, January 1, 202094009000000138761000
Friday, January 1, 2021103077000000187695000
Saturday, January 1, 2022113840000000581703000
Sunday, January 1, 2023202972000000709543000
Monday, January 1, 2024163607000000
Loading chart...

Unleashing insights

Gross Profit Trends: A Tale of Two Companies

In the competitive landscape of pharmaceuticals and diagnostics, Dr. Reddy's Laboratories Limited and Lantheus Holdings, Inc. have shown distinct trajectories in their gross profit over the past decade. Dr. Reddy's, a global pharmaceutical giant, has seen a remarkable growth in its gross profit, peaking in 2023 with a staggering 167% increase from 2014. This growth underscores its robust market presence and strategic expansions. In contrast, Lantheus Holdings, a leader in diagnostic imaging, has experienced a more modest growth, with its gross profit increasing by approximately 465% from 2014 to 2023. The data highlights a significant leap in 2022, suggesting a pivotal year for Lantheus. While Dr. Reddy's faced a dip in 2024, Lantheus's data for the same year remains unavailable, leaving room for speculation. These trends offer a fascinating glimpse into the financial health and strategic directions of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025